New drug cocktail targets Hard-to-Treat bladder cancer
NCT ID NCT04963153
First seen Jun 25, 2026 · Last updated Jul 31, 2026 · Updated 2 times
Summary
This early-phase trial is testing a combination of two drugs—erdafitinib and enfortumab vedotin—in 24 people with advanced bladder cancer that has spread and has specific FGFR2/3 gene changes. Erdafitinib blocks a faulty protein that helps cancer grow, while enfortumab vedotin delivers a toxin directly to cancer cells. The main goals are to find the safest dose and see if the combination can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- erdafitinib and enfortumab vedotin
- What this could lead to
- If this combination works, it could offer a new treatment option for people with advanced bladder cancer that has specific genetic changes.
- What could go wrong
- This is a very early phase 1 trial with only 24 participants, so it is mainly checking safety and dosing. The combination may not shrink tumors or could cause significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED BLADDER UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Los Angeles General Medical Center
Los Angeles, California, 90033, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
NYP/Weill Cornell Medical Center
New York, New York, 10065, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
UCHealth University of Colorado Hospital
Aurora, Colorado, 80045, United States
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
UT Southwestern/Simmons Cancer Center-Dallas
Dallas, Texas, 75390, United States
-
University Health Network-Princess Margaret Hospital
Toronto, Ontario, M5G 2M9, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted antibody-drug combo tackle rare bladder cancers?
- Targeted drug hunts down cancer cells in advanced bladder cancer trial
- New drug option for Hard-to-Treat cancers with FGFR3 mutations
- New bladder cancer drug aims to fight tumors without harming nerves
- New hope for advanced bladder cancer? bevacizumab combo tested
- New cocktail of drugs takes on Hard-to-Treat bladder cancer